199
Participants
Start Date
August 9, 2004
Primary Completion Date
January 8, 2007
Study Completion Date
January 8, 2007
Everolimus (Certican)
Vienna
Chermside
Innsbruck
New York Presbyterian Medical Center, New York
A Coruña
University of Pennsylvania Medical Center, Philadelphia
Temple University Hospital, Philadelphia
Milan
Kiel
Duke Clinical Research Institute, Durham
Oviedo
Tampa General Hospital, Tampa
St Luke's Medical Center, Milwaukee
University of Minnesota, Minneapolis
Texas Heart Institute/St Lukes Hospital, Houston
The Baylor College of Medicine/ The Methodist Hospital, Houston
Napoli
Cedar Sinai Medical Center, Los Angeles
The University of Alabama at Birmingham, Birmingham
Newark Beth Israel Medical Center, Newark
Darlinghurst
Belo Horizonte
Vancouver
Hanover
São Paulo
Toronto
Barcelona
Llobregat
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY